Medicines for Europe welcomes the publication of the ‘Joint Report on Health Care and Long-Term Care Systems & Fiscal Sustainability’, prepared by the European Commission’s Directorate-General f

Generic medicines save European countries 100 billion euros per year

SOPHARMA AD hereby informs that in accordance with its transparency policy and led by the internationally accepted best practices in the area of corporate governance Sopharma AD will continue to publish its individual and consolidated quarterly financial statements in full in service of its shareholders and the investment community.

 We also notify that the company now publishes all regulated information on the web site www.sopharmagroup.eu - the new website of Sopharma Group.

The company registered medicines in Sweden, too

Hardly 2017 will be the revolutionary year for Sopharma, but this may happen in 2018 – on original, Bulgarian molecule from Sopharma will be released on the global market. This is what we are working for and what would entirely change the image of our company. Everything else is an extensive development. This was said by Ognian Donev, the CEO of Sopharma, in an interview for Investor.bg, broadcasted on Bloomberg TV Bulgaria.

Twice as many patients treated in Europe because of generic medicine

“Medicines for Europe” strongly supports the French government campaign to boost generic medicines. Thanks to generic medicines, in Europe twice as many patients in 7 key therapeutic areas [1] (diabetes, depression, epilepsy, cardiovascular disease, hypertension, asthma/COPD, gastro-intestinal disease) have been able to be treated over the last ten years with no impact on overall treatment costs.